Remdesivir
| Evidence Level: L5 | Predicted Indications: 50 |
Quick Overview
| Item | Value |
|---|---|
| Drug Name | Remdesivir |
| DrugBank ID | DB14761 |
| Brand Names (EU) | Veklury |
| Evidence Level | L5 |
| Predicted Indications | 50 |
| Top Prediction Score | 99.50% |
Approved Indication (EMA)
Veklury is indicated for the treatment of coronavirus disease 2019 (COVID 19) in adults and paediatric patients (at least 4 weeks of age and weighing at least 3 kg): with pneumonia requiring supplemental oxygen (low- or high-flow oxygen or other non-invasive ventilation at start of treatment) who do not require supplemental oxygen and who are at increased risk of progressing to severe COVID-19 (see section 5.1)
Predicted New Indications
TxGNN model predictions for potential drug repurposing:
| Rank | Indication | Score | Source |
|---|---|---|---|
| 1 | multiple endocrine neoplasia | 99.50% | DL |
| 2 | HIV infectious disease | 99.32% | DL |
| 3 | feline acquired immunodeficiency syndrome | 99.07% | DL |
| 4 | simian immunodeficiency virus infection | 99.07% | DL |
| 5 | neurodevelopmental disorder with ataxic gait, absent speech, and decreased cortical white matter | 99.03% | DL |
| 6 | homozygous familial hypercholesterolemia | 99.03% | DL |
| 7 | Prinzmetal angina | 98.34% | DL |
| 8 | leprosy | 97.37% | DL |
| 9 | antithrombin deficiency type 2 | 97.25% | DL |
| 10 | cytomegalovirus infection | 97.08% | DL |
| 11 | factor 5 excess with spontaneous thrombosis | 96.99% | DL |
| 12 | heparin cofactor 2 deficiency | 96.95% | DL |
| 13 | infectious bovine rhinotracheitis | 96.89% | DL |
| 14 | malignant catarrh | 96.89% | DL |
| 15 | oral candidiasis | 96.83% | DL |
| 16 | hyperthyroidism | 96.79% | DL |
| 17 | hypoalphalipoproteinemia | 96.70% | DL |
| 18 | resistance to thyroid hormone due to a mutation in thyroid hormone receptor beta | 96.62% | DL |
| 19 | conjunctivitis | 96.57% | DL |
| 20 | commissural lip fistula | 96.56% | DL |
Showing top 20 of 50 predictions.
About TxGNN Predictions
Prediction Sources
| Source | Description |
|---|---|
| KG | Knowledge Graph - Network topology-based associations |
| DL | Deep Learning - Neural network score prediction |
Evidence Levels
| Level | Definition |
|---|---|
| L1 | Multiple Phase 3 RCTs / Systematic Reviews |
| L2 | Single RCT or multiple Phase 2 trials |
| L3 | Observational studies / Large case series |
| L4 | Preclinical / Mechanistic / Case reports |
| L5 | AI prediction only (current) |
Clinical Validation Needed
Research Use Only: These predictions are computational hypotheses that require clinical validation. They should NOT be used for clinical decision-making.
Next Steps for Validation
- Literature Review: Search PubMed for existing evidence
- Clinical Trial Search: Check ClinicalTrials.gov for ongoing studies
- Mechanistic Analysis: Evaluate biological plausibility
- Preclinical Studies: Conduct in vitro/in vivo validation
- Clinical Trials: Design and conduct human studies
Data Access
- FHIR API:
/fhir/ClinicalUseDefinition/ - CSV Download: All Predictions
- GitHub: yao-care/EuTxGNN
Citation
If using this data, please cite:
@article{huang2023txgnn,
title={A foundation model for clinician-centered drug repurposing},
author={Huang, Kexin and others},
journal={Nature Medicine},
year={2023},
doi={10.1038/s41591-023-02233-x}
}
Disclaimer: This report is for research purposes only and does not constitute medical advice. Drug repurposing predictions require rigorous clinical validation before any therapeutic application.